Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Revenues from Contract with Customers

v3.22.1
Revenues from Contract with Customers
12 Months Ended
Dec. 31, 2021
Revenue [Abstract]  
Revenues from contract with customers

6. Revenues from contract with customers

Disaggregated revenue information

The table below shows the disaggregation of the Group’s revenue from contracts with external customers:

 

 

 

For the year ended December 31, 2021

 

(EUR thousand)

 

Biopharmaceutical and Diagnostic Solutions

 

 

Engineering

 

 

Total

 

Type of goods or service

 

 

 

 

 

 

 

 

 

Revenues from high-value solutions

 

 

207,815

 

 

 

 

 

 

207,815

 

Revenues from other containment and delivery solutions

 

 

486,223

 

 

 

 

 

 

486,223

 

Revenues from engineering

 

 

 

 

 

149,882

 

 

 

149,882

 

Total revenue from contracts with customers

 

 

694,038

 

 

 

149,882

 

 

 

843,920

 

 

 

 

 

 

 

 

 

 

 

Geographical markets

 

 

 

 

 

 

 

 

 

EMEA

 

 

415,489

 

 

 

77,985

 

 

 

493,474

 

APAC

 

 

79,463

 

 

 

38,284

 

 

 

117,747

 

North America

 

 

175,231

 

 

 

31,730

 

 

 

206,961

 

South America

 

 

23,855

 

 

 

1,883

 

 

 

25,738

 

Total revenue from contracts with customers

 

 

694,038

 

 

 

149,882

 

 

 

843,920

 

 

 

 

 

 

 

 

 

 

 

Timing of revenue recognition

 

 

 

 

 

 

 

 

 

Goods and services transferred at a point in time

 

 

667,717

 

 

 

35,477

 

 

 

703,194

 

Goods and services transferred over time

 

 

26,321

 

 

 

114,405

 

 

 

140,726

 

Total revenue from contracts with customers

 

 

694,038

 

 

 

149,882

 

 

 

843,920

 

 

 

 

For the year ended December 31, 2020

 

(EUR thousand)

 

Biopharmaceutical and Diagnostic Solutions

 

 

Engineering

 

 

Total

 

Type of goods or service

 

 

 

 

 

 

 

 

 

Revenues from high-value solutions

 

 

146,332

 

 

 

 

 

 

146,332

 

Revenues from other containment and delivery solutions

 

 

418,599

 

 

 

 

 

 

418,599

 

Revenues from engineering

 

 

 

 

 

97,106

 

 

 

97,106

 

Total revenue from contracts with customers

 

 

564,931

 

 

 

97,106

 

 

 

662,037

 

 

 

 

 

 

 

 

 

 

 

Geographical markets

 

 

 

 

 

 

 

 

 

EMEA

 

 

338,564

 

 

 

59,575

 

 

 

398,139

 

APAC

 

 

54,433

 

 

 

12,702

 

 

 

67,135

 

North America

 

 

151,418

 

 

 

23,501

 

 

 

174,919

 

South America

 

 

20,516

 

 

 

1,328

 

 

 

21,844

 

Total revenue from contracts with customers

 

 

564,931

 

 

 

97,106

 

 

 

662,037

 

 

 

 

 

 

 

 

 

 

 

Timing of revenue recognition

 

 

 

 

 

 

 

 

 

Goods and services transferred at a point in time

 

 

553,789

 

 

 

38,417

 

 

 

592,207

 

Goods and services transferred over time

 

 

11,142

 

 

 

58,689

 

 

 

69,830

 

Total revenue from contracts with customers

 

 

564,931

 

 

 

97,106

 

 

 

662,037

 

 

 

 

For the year ended December 31, 2019

 

(EUR thousand)

 

Biopharmaceutical and Diagnostic Solutions

 

 

Engineering

 

 

Total

 

Type of goods or service

 

 

 

 

 

 

 

 

 

Revenues from high-value solutions

 

 

90,700

 

 

 

 

 

 

90,700

 

Revenues from other containment and delivery solutions

 

 

364,341

 

 

 

 

 

 

364,341

 

Revenues from engineering

 

 

 

 

 

81,498

 

 

 

81,498

 

Total revenue from contracts with customers

 

 

455,041

 

 

 

81,498

 

 

 

536,539

 

 

 

 

 

 

 

 

 

 

 

Geographical markets

 

 

 

 

 

 

 

 

 

EMEA

 

 

270,339

 

 

 

52,485

 

 

 

322,824

 

APAC

 

 

41,129

 

 

 

14,393

 

 

 

55,522

 

North America

 

 

119,054

 

 

 

13,381

 

 

 

132,435

 

South America

 

 

24,519

 

 

 

1,239

 

 

 

25,758

 

Total revenue from contracts with customers

 

 

455,041

 

 

 

81,498

 

 

 

536,539

 

 

 

 

 

 

 

 

 

 

 

Timing of revenue recognition

 

 

 

 

 

 

 

 

 

Goods and services transferred at a point in time

 

 

455,041

 

 

 

33,684

 

 

 

488,725

 

Goods and services transferred over time

 

 

 

 

 

47,814

 

 

 

47,814

 

Total revenue from contracts with customers

 

 

455,041

 

 

 

81,498

 

 

 

536,539

 

The Group revenues are divided into two main segments:

-
Biopharmaceutical and Diagnostic Solutions: this segment includes all the products and services developed and provided for containment and delivery of pharmaceutical drugs and diagnostic reagents. This segment is further divided into two sub-categories:
o
High-value solutions: wholly owned, internally developed products, processes and services for which the Group hold intellectual property rights or have strong proprietary know-how and are characterized by particular complexity or high performance;
o
Other containment and delivery solutions.
-
Engineering: this segment includes all the equipment and technologies developed and provided to support the end-to-end pharmaceutical and diagnostic manufacturing processes.

Consolidated revenues at current exchange rates increase by EUR 181,883 thousand, or 27.5%, to EUR 843,920 thousand for the year ended December 31, 2021, compared to EUR 662,037 thousand for the year ended December 31, 2020, which in turn increase by EUR 125,498 thousand, or 23.4%, compared to EUR 536,539 thousand for the year ended December 31, 2019. Currency movements in USD had a negative impact in 2021. Excluding this effect, consolidated revenues at constant currency exchange rates increase by 28.2% for the year ended December 31, 2021.

With reference to Biopharmaceutical and Diagnostic Solutions segment, revenues in high-value solutions increase by EUR 55,632 thousand, or 61.3% to EUR 146,332 thousand for the year ended December 31, 2020, compared to EUR 90,700 thousand for the year ended December 31, 2019; revenues on high-value solutions further increase by EUR 61,483 thousand or 42.0% to EUR 207,815 thousand for the year ended December 31, 2021. Revenues in other containment and delivery solutions increase by EUR 54,258 thousand, or 14.9%, from EUR 364,341 thousand for the year ended December 31, 2019 to EUR 418,599 thousand for the year ended December 31, 2020 and by further EUR 67,624 thousand, or 16.2%, to EUR 486,223 thousand for the year ended December 31, 2021.

Engineering segment revenues from contracts with external customers increase by EUR 15,608 thousand, or 19.1%, to EUR 97,106 thousand for the year ended December 31, 2020 compared to EUR 81,498 thousand for the year ended December 31, 2019; revenues further increase by EUR 52,776 thousand, or 54.3%, to EUR 149,882 thousand for the year ended December 31, 2021.

For the year ended December 31, 2021, revenues show an increase in all the geographic markets with the higher growth in the APAC market (+75.4%). Revenues increase by 18.3% in North America, by 17.8 % in South America and by 23.9% in EMEA, the Group traditional market.

For the year ended December 31, 2021, revenues related to goods and services transferred over time increase by EUR 15,179 thousand, or 136.2%, in the In-Vitro Diagnostic business. Revenues recognized over time increase also in the Engineering segment by EUR 55,716 thousand, or 94.9%, mainly due to the increasing progress on orders where enforceable right is ensured by contractual conditions.

Contract balances

The following table provides information on contractual asset from contracts with customer:

 

 

 

At December 31,

 

 

At December 31,

 

(EUR thousand)

 

2021

 

 

2020

 

Trade Receivables

 

 

165,259

 

 

 

127,818

 

Contract Assets

 

 

62,133

 

 

 

39,430

 

Contract Liabilities

 

 

(18,771

)

 

 

(5,031

)

Advances From Customers

 

 

(23,616

)

 

 

(48,361

)

Total

 

 

185,005

 

 

 

113,856

 

 

The contract assets mainly relate to the Group’s right to consideration for productions from construction contract not yet invoiced as of the balance sheet date. The amount recognized as contract assets are reclassified to trade receivable as soon as the Groups has an unconditional right to consideration.

Revenue recognized in the current reporting period relates to carried-forward contract liabilities amount to EUR 11,736 thousand in 2021 (respectively EUR 19,765 thousand in 2020 and EUR 17,218 thousand in 2019). As of December 31, 2021, the aggregate amount of the transaction price allocated to the remaining performance obligation is EUR 74,996 thousand (EUR 56,417 thousand as of December 31, 2020) and the Group will recognize this revenue as projects are completed, which is expected to occur over the next 12–18 months.